Intellia Therapeutics (NTLA) said Tuesday that the US Food and Drug Administration has lifted a hold on the Investigational New Drug application for the Magnitude-2 phase 3 trial of Nexiguran Ziclumeran for patients with hereditary transthyretin amyloidosis with polyneuropathy.

The study will now have an increased target enrollment of 60 patients from 50 patients with hereditary transthyretin amyloidosis with polyneuropathy, according to Intellia. The primary endpoints of the study are a change in modified neuropathy impairment score and a change in serum transthyretin levels, the company said.

Shares of the company were up 20% in recent Tuesday premarket activity.